Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
NCT06734130Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in prostate cancer (PCa), sponsored by Moffitt Cancer Center. Started Jan 2025; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06734130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734130.